Raxibacumab
http://dbpedia.org/resource/Raxibacumab an entity of type: Thing
Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys. In December 2012 raxibacumab was approved in the United States for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
rdf:langString
rdf:langString
Raxibacumab
xsd:integer
9701593
xsd:integer
1102283711
rdf:langString
BC02
rdf:langString
J06
xsd:integer
6320
xsd:integer
565451
rdf:langString
none
rdf:langString
DB08902
xsd:integer
9794
xsd:integer
1702
xsd:integer
1998
xsd:integer
42
rdf:langString
u
rdf:langString
Protective antigen of anthrax toxin
rdf:langString
mab
xsd:integer
794
rdf:langString
changed
xsd:integer
464380354
rdf:langString
changed
rdf:langString
Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys. In December 2012 raxibacumab was approved in the United States for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. The antibody was discovered in a joint venture between Cambridge Antibody Technology and Human Genome Sciences. Cambridge Antibody Technology discovered the antibody to Human Genome Sciences's target and, in 2012, HGS were purchased by GlaxoSmithKline (GSK). In 2017, it was acquired by Emergent BioSolutions
rdf:langString
mab
xsd:nonNegativeInteger
6276
xsd:string
565451-13-0
xsd:string
DB08902
xsd:string
794PGL549S